Longterm results of auranofin therapy

Area of Science:

• Rheumatology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease requiring long-term management.
• Auranofin, an oral gold preparation, has been used for RA treatment.
• Evaluating long-term efficacy and safety is crucial for therapeutic decision-making.

Purpose of the Study:

• To assess the long-term therapeutic outcomes of auranofin in rheumatoid arthritis (RA) patients.
• To evaluate the safety profile of auranofin through multicenter studies and postmarketing surveillance.
• To identify factors influencing treatment response in RA patients receiving auranofin.

Main Methods:

• Analysis of data from two multicenter open uncontrolled studies (MTC06, 162EMUA-RA).
• Reevaluation of MTC06 study data after four years.
• Inclusion of results from a postmarketing surveillance program (PMSP).
• Utilized the rheumatologic documentation and information system (IKR).

Main Results:

• Disease duration under two years was the primary factor for positive treatment outcomes.
• Patients responding favorably to auranofin maintained good outcomes over four years or longer.
• No new severe or threatening side effects were identified.
• Common initial side effects included diarrhea and loose stools; overall withdrawal for adverse events was 11.2%.
• Auranofin was effective even in patients with prior adverse events to other DMARDs.

Conclusions:

• Long-term auranofin therapy in RA patients demonstrates sustained efficacy.
• Early diagnosis and treatment initiation correlate with better outcomes.
• Auranofin exhibits a favorable safety profile, with manageable side effects.
• It serves as a viable treatment option, even for patients intolerant to other DMARDs.